Company: IMNN
Filing Date: 2025-05-13
Form Type: S-1/A
Source: 0001641172-25-009814
Chunk: 26

Company: Imunon, Inc.
Filing Date: 2025-05-13
Form: S-1/A
Chunk 26
---
 warrants as of March 31, 2025, having a weighted average 
 exercise price of $2.51 per share; and                                                                                    |
| ● | 223,522                                                                                                                   
 shares of Common Stock reserved for future issuance                                                                       
 pursuant to our existing stock incentive plan.                                                                            |

To the extent that any outstanding stock options or warrants are exercised, new stock options are issued under our stock incentive plans, or we otherwise issue additional shares of Common Stock or securities convertible into or exercisable for Common Stock in the future, at a price less than the public offering price, there will be further dilution to new investors.

The information discussed above is illustrative only and will adjust based on the actual public offering price and other terms of this offering determined at pricing. Except as indicated otherwise, the discussion and table above assume no exercise of common warrants offered hereby and no sale of pre-funded warrants, which, if sold, would reduce the number of shares of Common Stock that we are offering on a one-for-one basis. The foregoing discussion and table also does not take into account any “alternative cashless exercises” of the common warrants, pursuant to which a holder of a common warrant has the right to receive an aggregate number of shares equal to the product of (i) the aggregate number of shares of Common Stock that would be issuable upon a cash rather than a cashless exercise of the common warrant and (ii) 3.0.

| 11 |

<div align='center'>USE OF PROCEEDS</div>

We estimate that we will receive net proceeds from this offering of approximately $10.9 million (assuming the sale of the maximum number of securities offered hereby), based upon an assumed public offering price of $0.80 per share of Common Stock and accompanying common warrant (which is the last reported sale price of our Common Stock on Nasdaq on May 9, 2025), after deducting the estimated Placement Agent fees and estimated offering expenses payable by us and assuming no issuance of any pre-funded warrants and no exercise of the common warrants. However, because this is a reasonable best-efforts offering with no minimum number of securities or amount of proceeds as a condition to closing, the actual offering amount, Placement Agent fees, and net proceeds to us are not presently determinable and may be substantially less than the maximum amounts set forth on the cover page of this prospectus, and we may not sell all or any of the securities we are offering. As a result, we may receive significantly less in net proceeds. Based on the